{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:51:14Z","timestamp":1787964674415,"version":"build-2784847793"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>In X\u2010linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH]<jats:sub>2<\/jats:sub>D) concentration, with subsequent development of rickets or osteomalacia. KRN23 is a recombinant human IgG1 monoclonal antibody that binds to FGF23 and blocks its activity. Up to 4 doses of KRN23 were administered subcutaneously every 28 days to 28 adults with XLH. Mean\u2009\u00b1\u2009standard deviation KRN23 doses administered were 0.05, 0.10\u2009\u00b1\u20090.01, 0.28\u2009\u00b1\u20090.06, and 0.48\u2009\u00b1\u20090.16\u2009mg\/kg. The mean time to reach maximum serum KRN23 levels was 7.0 to 8.5 days. The mean KRN23 half\u2010life was 16.4 days. The mean area under the concentration\u2013time curve (AUC<jats:sub>n<\/jats:sub>) for each dosing interval increased proportionally with increases in KRN23 dose. The mean intersubject variability in AUC<jats:sub>n<\/jats:sub> ranged from 30% to 37%. The area under the effect concentration\u2013time curve (AUEC<jats:sub>n<\/jats:sub>) for change from baseline in TmP per glomerular filtration rate, serum Pi, 1,25(OH)<jats:sub>2<\/jats:sub>D, and bone markers for each dosing interval increased linearly with increases in KRN23 AUC<jats:sub>n<\/jats:sub>. Linear correlation between serum KRN23 concentrations and increase in serum Pi support KRN23 dose adjustments based on predose serum Pi concentration. \u00a9 2015 The Authors. <jats:italic>The Journal of Clinical Pharmacology<\/jats:italic> Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.570","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T22:08:09Z","timestamp":1434146889000},"page":"176-185","source":"Crossref","is-referenced-by-count":47,"title":["Pharmacokinetics and pharmacodynamics of a human monoclonal anti\u2010FGF23 antibody (KRN23) in the first multiple ascending\u2010dose trial treating adults with X\u2010linked hypophosphatemia"],"prefix":"10.1002","volume":"56","author":[{"given":"Xiaoping","family":"Zhang","sequence":"first","affiliation":[{"name":"Kyowa Hakko Kirin Pharma Inc. Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary D.","family":"Ruppe","sequence":"additional","affiliation":[{"name":"The Methodist Hospital Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Weber","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Klausner","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin Pharma Inc. Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin Pharma Inc. Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vergeire","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin Pharma Inc. Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Humphrey","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin Pharma Inc. Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis H.","family":"Glorieux","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Portale","sequence":"additional","affiliation":[{"name":"University of California San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Insogna","sequence":"additional","affiliation":[{"name":"Yale Center for X\u2010Linked Hypophosphatemia, Yale University School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Yale Center for X\u2010Linked Hypophosphatemia, Yale University School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munro","family":"Peacock","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"issue":"2565","key":"e_1_2_8_2_1","first-page":"2575","article-title":"Fibroblast growth factor 23: roles in health and disease","volume":"16","author":"Imel EA","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007010068"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1768"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.102"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90742.2008"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(64)90085-3"},{"key":"e_1_2_8_8_1","unstructured":"TenenhouseHS EconsNJ.Mendelian Hypophosphatemia. The Online Metabolic and Molecular Bases of Inherited Diseases(OMMBID); Part 21 (Chap. 197).http:\/\/www.ommbid.com\/OMMBID\/the_online_metabolic_and_molecular_bases_of_inherited_disease\/b\/abstract\/part21\/ch197. Accessed October 1 2013."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198911000-00002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1977.tb03387.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010303031802"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111900"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-3-463"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080417"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090509"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72829"},{"key":"e_1_2_8_18_1","article-title":"Pharmacokinetics and pharmacodynamics of a human monoclonal anti\u2010FGF23 antibody (KRN23) after single\u2010dose administration to patients with X\u2010linked hypophosphatemia","volume":"28","author":"Zhang X","year":"2013","journal-title":"J Bone Miner Res"},{"key":"e_1_2_8_19_1","unstructured":"ImelEA ZhangX RuppeMD et al. The First Multi\u2010Dose Trial of a Human Anti\u2010FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X\u2010Linked Hypophosphatemia (XLH). Oral presentation (OR43\u20101). 2014 ICE\/ENDO Annual Meeting. June 21\u201324 2014. Chicago Illinois."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.02.014"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/000456329803500203"},{"key":"e_1_2_8_22_1","unstructured":"GibaldiM.PerrierD. Non\u2010compartmental analysis based on statistical moment theory. In:Pharmacokinetics (Drugs and the Pharmaceutical Sciences). 2nd ed. New York New York: Marcel Decker Inc.;1982409\u2013417."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105"},{"key":"e_1_2_8_24_1","unstructured":"Investigator Laboratory Instruction Manual. Quest Diagnostics Clinical Trials. Valencia California."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92736-1"},{"key":"e_1_2_8_26_1","unstructured":"Investigator Laboratory Instruction Manual. Esoterix Clinical Trials Services. A division of LabCorp. Cranford New Jersey."},{"key":"e_1_2_8_27_1","first-page":"2327","article-title":"Pharmacokinetics of therapeutic monoclonal antibodies used in oncology","volume":"25","author":"Leveque D","year":"2005","journal-title":"Anticancer Res."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.570","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.570","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T12:53:08Z","timestamp":1696510388000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1002\/jcph.570"],"URL":"https:\/\/doi.org\/10.1002\/jcph.570","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}